Table 6 Clinical trials-lenalidomide (Relapsed/refractory disease)
From: Thalidomide and its analogues in the treatment of Multiple Myeloma
Author | Regimen(s) | Type of clinical trial | No. of pts | Best responses (>PR) | CR, nCR, VGPR | PFS/TTP/OS (months) | Reference |
|---|---|---|---|---|---|---|---|
Dimopoulus et al | LD | Phase III | 351 | 60.2% vs. 24% | CR+nCR:15.9% vs. 3.4% | TTP:11.7 vs. 4.7 OS:Not reached vs. 20.7 | N Engl J Med 2007 |
Weber et al | LD | Phase IIII | 353 | 61% vs. 19.9% | CR:14.4 vs. 0.6% | TTP:11.7 vs. 4.7 OS:29.6 vs. 20.2 | N. Engl J Med 2007 |
Palumbo et al | MPL-L | Phase III | 459 | 77% vs. 49% | CR:18% vs. 5% | Not reached | ASH 2009 ASCO 2010 |